MRNA: Morgan Stanley keeps Equalweight, raises PT to $89
Morgan Stanley maintains an Equalweight rating on MRNA and raises its price target to $89, according to TradeXchange Newsdesk.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.